PMID- 32083810
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20201123
IS  - 1934-6638 (Electronic)
IS  - 1934-662X (Linking)
VI  - 128
IP  - 7
DP  - 2020 Jul
TI  - Urine cytology suspicious for urothelial carcinoma: Prospective follow-up of 
      cases using cytology and urine biomarker-based ancillary techniques.
PG  - 460-469
LID - 10.1002/cncy.22252 [doi]
AB  - BACKGROUND: Urine cytology results that are suspicious for urothelial carcinoma 
      (UC) are challenging. The objective of this study was to elucidate the clinical 
      significance of such results in patients who have a negative cystoscopy. METHODS: 
      In this prospective study, 83 patients who had urine cytology that was suspicious 
      of UC and a negative cystoscopy underwent a second cystoscopy and urine 
      evaluation by cytology, UroVysion fluorescence in situ hybridization (FISH) 
      assay, FGFR3 (fibroblast growth factor receptor 3) and TERT (telomerase reverse 
      transcriptase) mutations and an 8-gene expression classifier (GEC). Results from 
      all techniques were compared with patients' clinical outcomes. RESULTS: The 
      presence of tumor was identified in 41% of patients; of these, 82% had tumors 
      identified at their second evaluation (76% high-grade [HG] tumors), and 18% had 
      tumors identified at a later follow-up (50% were HG tumors). After The Paris 
      System for Reporting urinary Cytology (TPS) reclassification, 53 cytology results 
      still had an indeterminate diagnosis (13 were suspicious for HGUC, and 40 had 
      atypical urothelial cells (AUCs)]. Complete results from second evaluations using 
      urine cytology, cytology-TPS, FISH, and GEC were available for 6 cases that were 
      suspicious for HGUC and 34 cases that had AUCs. The sensitivity of these 
      techniques to detect HG tumors in cases that were suspicious for HGUC was 100%, 
      except for cytology-TPS, for which the sensitivity was 50%. The sensitivity of 
      cytology and cytology-TPS to detect HG tumors in cases with AUCs was 33%, whereas 
      the sensitivity of fluorescence in situ hybridization and GEC in these cases was 
      83% and 75%, respectively, to detect HG tumors at the second evaluation. 
      CONCLUSIONS: The current results indicate the relevant clinical significance of 
      indeterminate urine cytology findings and strongly suggest the use of 
      complementary evaluations by urine biomarker-based, ancillary techniques to 
      elucidate their significance.
CI  - (c) 2020 American Cancer Society.
FAU - Montalbo, Ruth
AU  - Montalbo R
AD  - Laboratory and Department of Urology, Hospital Clinic, Institut d'Investigacions 
      Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, 
      Spain.
FAU - Izquierdo, Laura
AU  - Izquierdo L
AD  - Laboratory and Department of Urology, Hospital Clinic, Institut d'Investigacions 
      Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, 
      Spain.
FAU - Ingelmo-Torres, Mercedes
AU  - Ingelmo-Torres M
AD  - Laboratory and Department of Urology, Hospital Clinic, Institut d'Investigacions 
      Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, 
      Spain.
FAU - Galve, Pilar
AU  - Galve P
AD  - Laboratory and Department of Urology, Hospital Clinic, Institut d'Investigacions 
      Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, 
      Spain.
FAU - Sole, Manel
AU  - Sole M
AD  - Department of Pathology, Hospital Clinic, Barcelona, Spain.
FAU - Franco, Agustin
AU  - Franco A
AD  - Laboratory and Department of Urology, Hospital Clinic, Institut d'Investigacions 
      Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, 
      Spain.
FAU - Ribal, Maria Jose
AU  - Ribal MJ
AD  - Laboratory and Department of Urology, Hospital Clinic, Institut d'Investigacions 
      Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, 
      Spain.
FAU - Alcaraz, Antonio
AU  - Alcaraz A
AD  - Laboratory and Department of Urology, Hospital Clinic, Institut d'Investigacions 
      Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, 
      Spain.
FAU - Mengual, Lourdes
AU  - Mengual L
AUID- ORCID: 0000-0001-7418-9422
AD  - Laboratory and Department of Urology, Hospital Clinic, Institut d'Investigacions 
      Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, 
      Spain.
LA  - eng
PT  - Journal Article
DEP - 20200221
PL  - United States
TA  - Cancer Cytopathol
JT  - Cancer cytopathology
JID - 101499453
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*genetics
MH  - Cytodiagnosis/*methods
MH  - Female
MH  - Follow-Up Studies
MH  - *Gene Expression Profiling
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Prognosis
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Urinalysis/*methods
MH  - Urologic Neoplasms/*diagnosis/genetics
OTO - NOTNLM
OT  - bladder cancer
OT  - cytology
OT  - fluorescence in situ hybridization (FISH) technique
OT  - gene expression
OT  - patient monitoring
OT  - tumor biomarkers
OT  - urine
EDAT- 2020/02/23 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/02/22 06:00
PHST- 2019/09/20 00:00 [received]
PHST- 2020/01/13 00:00 [revised]
PHST- 2020/01/16 00:00 [accepted]
PHST- 2020/02/23 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
PHST- 2020/02/22 06:00 [entrez]
AID - 10.1002/cncy.22252 [doi]
PST - ppublish
SO  - Cancer Cytopathol. 2020 Jul;128(7):460-469. doi: 10.1002/cncy.22252. Epub 2020 
      Feb 21.